About Novo Nordisk A/S
Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company's business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity. The biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. It offers a range of diabetes product, including new generation insulins and a portfolio of modern insulin. It provides Saxenda, which is a product to treat obesity and is available in Denmark, Italy and Canada. Its other products/compounds include Xultophy, Semaglutide (NN9535), Faster-acting insulin aspart (NN1218), N9-GP (NN7999), N8-GP (NN7088) and NN8640 Once-weekly human growth hormone.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Exchange: NYSE
- Symbol: NVO
- Previous Close: $35.78
- 50 Day Moving Average: $35.29
- 200 Day Moving Average: $38.79
- 52-Week Range: $30.89 - $57.81
- Trailing P/E Ratio: 16.67
- Foreward P/E Ratio: 14.79
- P/E Growth: 1.68
- Market Cap: $89.60B
- Outstanding Shares: 2,504,332,000
- Beta: 0.83
- Net Margins: 33.97%
- Return on Equity: 90.61%
- Return on Assets: 42.44%
Companies Related to Novo Nordisk A/S:
- Current Ratio: 1.26%
- Quick Ratio: 0.96%
What is Novo Nordisk A/S's stock symbol?
Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."
How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?
Novo Nordisk A/S declared an annual dividend on Tuesday, February 7th. Stockholders of record on Monday, March 27th will be paid a dividend of $0.6634 per share on Tuesday, April 4th. This represents a dividend yield of 1.99%. The ex-dividend date of this dividend is Thursday, March 23rd.
Where is Novo Nordisk A/S's stock going? Where will Novo Nordisk A/S's stock price be in 2017?
13 brokerages have issued 1 year price objectives for Novo Nordisk A/S's shares. Their forecasts range from $57.00 to $57.00. On average, they expect Novo Nordisk A/S's stock price to reach $57.00 in the next year.
Who owns Novo Nordisk A/S stock?
Novo Nordisk A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Loomis Sayles & Co. L P (0.76%), Renaissance Technologies LLC (0.56%), FMR LLC (0.24%), Santa Barbara Asset Management LLC (0.09%), Capital Guardian Trust Co. (0.05%) and Franklin Resources Inc. (0.04%).
Who sold Novo Nordisk A/S stock? Who is selling Novo Nordisk A/S stock?
Novo Nordisk A/S's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Franklin Resources Inc., Artisan Partners Limited Partnership, First Republic Investment Management Inc., Ruane Cunniff & Goldfarb Inc., Teachers Retirement System of The State of Kentucky and Scotia Capital Inc..
Who bought Novo Nordisk A/S stock? Who is buying Novo Nordisk A/S stock?
Novo Nordisk A/S's stock was purchased by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Russell Investments Group Ltd., Two Sigma Investments LP, Hutchinson Capital Management CA, Marshall Wace LLP, Cutter & CO Brokerage Inc., Envestnet Asset Management Inc. and Headinvest LLC.
How do I buy Novo Nordisk A/S stock?
Shares of Novo Nordisk A/S can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Novo Nordisk A/S stock cost?
One share of Novo Nordisk A/S stock can currently be purchased for approximately $35.78.